2-Bromo-TMA

2-Bromo-TMA, or 2-Br-TMA, also known as 2-bromo-3,4,5-trimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine. It is the 2-brominated derivative of TMA. The drug's dose is approximately 200mg orally and its duration is approximately 8hours. Compared to TMA, 2-bromo-TMA is described as being only slightly less potent, being more active in altering visual perception, and having fewer physical side effects in comparison. 2-Bromo-TMA was described in the scientific literature by Daniel Trachsel and colleagues in 2013, who cited personal communication with P. Rausch in 2009 for the information. It is a controlled substance in Canada under phenethylamine blanket-ban language.